The FDA has granted emergency use authorization for the Aptima Zika virus assay system, from Hologic, for detection of the...
Luminex Corporation has received Emergency Use Authorization (EUA) from the FDA for a multiplex nucleic acid test called the xMAP...
Abbott announced that the U.S. FDA has authorised its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus...
Grifols announced that the FDA approved the Procleix Zika Virus assay for the detection of the virus in individual or...
Innovation Pharmaceuticals announced that brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract illness in young children and a major cause of hospital admissions globally.
These guidelines include a number of recommendations regarding HIV testing. The approaches described need to be adopted and adapted based on local HIV prevalence data, populations and services.
The immunopathology of respiratory syncytial virus (RSV) infection varies considerably, severe disease occurring only in a minority of the affected children.
Respiratory syncytial virus (RSV) is an enveloped RNA virus, in the same family as the human parainfluenza viruses and mumps and measles viruses
This meta-analysis aims to present a collective view on the relationship between viral infection and IPF.